Perseus Proteomics Inc. (TYO:4882)
Japan · Delayed Price · Currency is JPY 255.00
+1.00 (0.39%)
Jan 22, 2026, 3:30 PM JST
Perseus Proteomics Balance Sheet
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2018 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2018 - 2020 |
Cash & Equivalents | 1,385 | 1,667 | 1,541 | 2,444 | 3,214 | 1,069 | Upgrade |
Cash & Short-Term Investments | 1,385 | 1,667 | 1,541 | 2,444 | 3,214 | 1,069 | Upgrade |
Cash Growth | -33.61% | 8.18% | -36.95% | -23.96% | 200.65% | 121.78% | Upgrade |
Accounts Receivable | 15 | 22 | 13 | 9 | 10 | 8 | Upgrade |
Other Receivables | 19 | 50 | 70 | 41 | 35 | 21 | Upgrade |
Receivables | 34 | 72 | 83 | 50 | 45 | 29 | Upgrade |
Inventory | 11 | 5 | 4 | 3 | 3 | 1 | Upgrade |
Prepaid Expenses | 13 | 11 | 5 | 7 | 4 | 4 | Upgrade |
Other Current Assets | 4 | 20 | 17 | 10 | 24 | 5 | Upgrade |
Total Current Assets | 1,447 | 1,775 | 1,650 | 2,514 | 3,290 | 1,108 | Upgrade |
Long-Term Investments | 14 | 42 | 42 | 51 | 9 | 9 | Upgrade |
Other Long-Term Assets | - | 1 | 1 | 1 | 1 | 1 | Upgrade |
Total Assets | 1,461 | 1,818 | 1,693 | 2,566 | 3,300 | 1,118 | Upgrade |
Accounts Payable | - | - | 1 | 1 | - | 1 | Upgrade |
Accrued Expenses | 36 | 41 | 57 | 28 | 11 | 8 | Upgrade |
Current Income Taxes Payable | 56 | 79 | 66 | 66 | 134 | 24 | Upgrade |
Other Current Liabilities | 5 | 4 | 4 | 16 | 3 | 1 | Upgrade |
Total Current Liabilities | 97 | 124 | 128 | 111 | 148 | 34 | Upgrade |
Other Long-Term Liabilities | 312 | 262 | 167 | 59 | - | 1 | Upgrade |
Total Liabilities | 409 | 386 | 295 | 170 | 148 | 35 | Upgrade |
Common Stock | 500 | 2,437 | 1,971 | 1,939 | 1,939 | 604 | Upgrade |
Additional Paid-In Capital | 853 | 2,723 | 2,256 | 2,225 | 2,225 | 889 | Upgrade |
Retained Earnings | -379 | -3,808 | -2,903 | -1,799 | -1,012 | -413 | Upgrade |
Comprehensive Income & Other | 78 | 80 | 74 | 31 | - | 3 | Upgrade |
Shareholders' Equity | 1,052 | 1,432 | 1,398 | 2,396 | 3,152 | 1,083 | Upgrade |
Total Liabilities & Equity | 1,461 | 1,818 | 1,693 | 2,566 | 3,300 | 1,118 | Upgrade |
Net Cash (Debt) | 1,385 | 1,667 | 1,541 | 2,444 | 3,214 | 1,069 | Upgrade |
Net Cash Growth | -33.61% | 8.18% | -36.95% | -23.96% | 200.65% | 121.78% | Upgrade |
Net Cash Per Share | 93.94 | 116.83 | 130.72 | 207.83 | 292.27 | 152.72 | Upgrade |
Filing Date Shares Outstanding | 14.75 | 14.75 | 11.85 | 11.76 | 11.75 | 8.36 | Upgrade |
Total Common Shares Outstanding | 14.75 | 14.75 | 11.85 | 11.76 | 11.75 | 8.36 | Upgrade |
Working Capital | 1,350 | 1,651 | 1,522 | 2,403 | 3,142 | 1,074 | Upgrade |
Book Value Per Share | 71.32 | 97.09 | 118.00 | 203.75 | 268.36 | 129.53 | Upgrade |
Tangible Book Value | 1,052 | 1,432 | 1,398 | 2,396 | 3,152 | 1,083 | Upgrade |
Tangible Book Value Per Share | 71.32 | 97.09 | 118.00 | 203.75 | 268.36 | 129.53 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.